HOWL vs. ALDX, TSVT, ME, FHTX, IMMP, VERU, PYXS, CDT, ACIU, and EBS
Should you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Aldeyra Therapeutics (ALDX), 2seventy bio (TSVT), 23andMe (ME), Foghorn Therapeutics (FHTX), Immutep (IMMP), Veru (VERU), Pyxis Oncology (PYXS), Conduit Pharmaceuticals (CDT), AC Immune (ACIU), and Emergent BioSolutions (EBS). These companies are all part of the "pharmaceutical preparations" industry.
Werewolf Therapeutics (NASDAQ:HOWL) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.
Werewolf Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500.
Aldeyra Therapeutics has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -256.33%. Aldeyra Therapeutics' return on equity of -24.69% beat Werewolf Therapeutics' return on equity.
Werewolf Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics received 457 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. Likewise, 69.36% of users gave Aldeyra Therapeutics an outperform vote while only 62.16% of users gave Werewolf Therapeutics an outperform vote.
Werewolf Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 154.24%. Aldeyra Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 136.29%. Given Werewolf Therapeutics' higher probable upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than Aldeyra Therapeutics.
64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 21.1% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Aldeyra Therapeutics had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 1 mentions for Aldeyra Therapeutics and 0 mentions for Werewolf Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.80 beat Werewolf Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.
Summary
Aldeyra Therapeutics beats Werewolf Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Werewolf Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Werewolf Therapeutics Competitors List
Related Companies and Tools
